Meet with... National Cancer Institute

Sep 11 2014

SF BAY AREA EVENT The National Cancer Institute (NCI) invites you to a special session to meet with NCI Small Business Innovation Research Development Center (NCI SBIR) leaders at Janssen Labs @Qb3 on September 11, 2014.

Program Overview:
NCI: New SBIR Opportunities for Early-Stage and Venture-Backed Companies

Director Michael Weingarten, Team Leader Andrew Kurtz, and Christie Canaria will discuss new non-dilutive contract funding opportunities available for early stage companies to develop the next generation of cancer technologies and therapeutics.

During this session, NCI leaders will provide an update on recently released funding opportunities available to small businesses as well as tips on strengthening your application. The SBIR program helps fill the gap in the availability of early stage funding created when investors and strategic partners move towards clinical-stage investments. SBIR funds serve as a key bridge between initial angel funding and more significant angel capital, venture capital, or strategic partnerships.

Additionally, the presentation will provide valuable information on NCI's other initiatives including the NCI SBIR Bridge Award, the NCI SBIR Investor Forum, and I-Corps™ at NIH. Get all of your questions answered during the Q&A session following the presentation.

9:30 AM | Registration & Networking session
10:00 AM | Michael Weingarten: "Overview of NCI SBIR Program"
10:25 AM | Andrew Kurtz: "Tips on applying"
10:50 AM | Christie Canaria: "Funding opportunities and contract topics"
11:15 AM | Q&A Session
12:00 PM | Program Close

National Cancer Institute Participating Representatives:
Michael Weingarten | Director, SBIR Development Center, National Cancer Institute read bio»
Andrew Kurtz, Ph.D. | Program Director & Team Leader, SBIR Development Center, National Cancer Institute read bio»
Christie Canaria, Ph.D. | AAAS Science & Technology Policy Fellow, SBIR Development Center, National Cancer Institute read bio»

About the National Cancer Institute:
The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

$25 | General Public
Includes presentation, Q&A, and refreshments.

QB3@953 Location:
953 Indiana Street
San Francisco, CA, 94107

National Cancer Institute Representatives' Biographies:
Michael Weingarten Michael Weingarten | Director, SBIR Development Center, National Cancer Institute
Michael Weingarten is the director for the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute, one of 27 Institutes of the National Institutes of Health (NIH) in Bethesda, MD. In this role, Mr. Weingarten manages all aspects of the NCI SBIR & STTR Programs including a portfolio of over $119M in grants and contracts annually. The SBIR & STTR programs are NCI's engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer.
In his current role, Mr. Weingarten led a team that developed a set of key recommendations for optimizing the performance of the NCI SBIR Program at the NIH. Those recommendations included the establishment of an SBIR Development Center to manage the NCI SBIR Program. This Center is staffed with talented leaders from both industry and the NIH who have expertise in the development and commercialization of technology in the cancer field to optimize the returns the NCI achieves through this program.
Mr. Weingarten also created and designed a brand new funding program for the NIH known as the SBIR Phase II Bridge Award, which more than triples the amount of funding available to applicants through the NCI SBIR Program. The Phase II Bridge Award will help small businesses "bridge" the funding gap known as the "Valley of Death," that currently exists between the end of the SBIR Phase II award and the next round of financing needed to advance a promising cancer therapy or imaging technology. The new Phase II Bridge Award is specifically designed to augment previously funded NIH-wide SBIR Phase II projects in the areas of cancer therapies and cancer imaging that require additional funding in order to achieve key technical and regulatory milestones along the path toward commercialization. This new award incentivizes partnerships between NIH's SBIR Phase II awardees and third-party investors and/or strategic partners.

Andrew Kurtz Andrew Kurtz, Ph.D. | Program Director & Team Leader, SBIR Development Center, National Cancer Institute
Dr. Kurtz is a Program Director in the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute. His management portfolio includes both grant and contract awards to support the pre-clinical development of novel oncology therapeutics, including small molecules, biologics, and multifunctional therapeutics based on nanotechnology. From 2005-2007, Dr. Kurtz was a NIH/AAAS Science and Technology Policy Fellow, serving on the management team of The Cancer Genome Atlas Pilot Project and also assisting in the development of several program enhancements to help advance NIH-funded SBIR projects toward commercialization.
Prior to coming to NIH, Dr. Kurtz conducted basic research in DNA repair, mutagenesis and carcinogenesis. He held a previous position as Research Associate at Cedra Corporation, a Contract Research Organization that provides GLP bioanalytical services to the pharmaceutical and biotechnology industries. Dr. Kurtz received a B.S. in Chemistry from The University of Texas at Austin, and a Ph.D. in Human Biological Chemistry & Genetics from The University of Texas Medical Branch at Galveston.

Christie Canaria Christie Canaria, Ph.D. | AAAS Science & Technology Policy Fellow, SBIR Development Center, National Cancer Institute
Christie Canaria has over 15 years of experience in academic, industrial, and government scientific research. Currently, Christie is expanding into the science policy sector as an AAAS Science & Technology Policy Fellow. She leverages her experiences in start-up company innovation, biotechnology, medical/biological imaging, and biosensor design in the Small Business Innovation Research Development Center of the National Cancer Institute under the National Institutes of Health.
From 2010 to 2013, Christie managed an optical microscopy facility at DOE Lawrence Berkeley National Laboratory as an imaging expert and neurobiologist. In addition, Christie worked at Illumina, Inc., then a small start-up company in San Diego. She witnessed Illumina's initial public offering in 2000 and its early development into a global leader in genomic sequencing.
Christie earned her Ph.D. in Chemistry from Caltech under the tutelage of Prof. Scott Fraser, Director of the Biological Imaging Center, where she created and developed intellectual property for bio/chemical sensors. She earned her B.S. in Chemistry from the University of California, San Diego with training from Prof. Michael Sailor.